Press Releases

2019.09.10

I-Mab Biopharma and Junshi Biosciences Announce Collaboration to Evaluate TJD5 in Combination with Toripalimab for the Treatment of Patients with Cancers in China

Shanghai, September 10, 2019, I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a co...

2019.08.01

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors

Shanghai and San Diego, CA –August 1, 2019 – I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and TRACON P...

2019.07.13

I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China

July 13 ,2019，Beijing, I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces that the National Medical Products Administration (NMPA) has approved its investigational...

2019.07.11

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), a China ...

2019.06.26

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

June 25, 2019，Gaithersburg, MD, I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019 that the first patient has been dosed in a Phase I clinical tri...

2019.04.29

I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma

I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), announced today that the first p...

2019.04.17

I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

SHANGHAI, April 16, 2019 -- I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, and WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutio...

2019.04.11

I-Mab Biopharma Signs Agreement for Clinical Research of TJD5 in Combination Therapy

I-Mab Biopharma (“I-Mab”), a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases enters into a collaboration with Roche for I-Mab’s clinical study to evaluate TJD5 in combin...

2019.04.08

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center

Boston, April 8th , 2019 -- I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and Jiangsu Nhwa Pharmaceutical (Nhwa), a company dev...

2019.03.20

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 19th, 2019 -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX &...